Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Heong, V. Y. M. [1 ]
Marme, F. [2 ]
Rugo, H. S. [3 ]
Tolaney, S. M. [4 ]
Bardia, A. [5 ]
Schmid, P. [6 ]
Verret, W. [7 ]
Valdez, T. [8 ]
Wang, H. [9 ]
Cortes, J. [10 ]
机构：
[1] Tan Tock Seng Hosp, Natl Healthcare Grp, Haematol Oncol Dept, Singapore, Singapore
[2] UMM Univ Klinikum Mannheim, Med Fak, Gynecol Oncol Dept, Mannheim, Germany
[3] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Med Oncol Dept, Boston, MA USA
[6] Barts & London Queen Marys Sch Med & Dent, Canc Res UK Barts Ctr, Ctr Expt Canc Med, London, England
[7] Gilead Sci Inc, Clin Dev, Miami, FL USA
[8] Gilead Sci Inc, Patient Safety, Miami, FL USA
[9] Gilead Sci Inc Headquarters, Clin Dev, Foster City, CA USA
[10] MEDSIR Med Sci Innovat Res, Quiron Grp Barcelona, Pangaea Oncol, Oncol Dept,Int Breast Canc Ctr IBCC, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.189
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
54O
引用
收藏
页码：S1486 / S1487
页数：2
相关论文
共 50 条
  • [1] TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer
    Rugo, Hope S.
    Bardia, Aditya
    Tolaney, Sara M.
    Arteaga, Carlos
    Cortes, Javier
    Sohn, Joohyuk
    Marme, Frederik
    Hong, Quan
    Delaney, Rosemary J.
    Hafeez, Amir
    Andre, Fabrice
    Schmid, Peter
    FUTURE ONCOLOGY, 2020, 16 (12) : 705 - 715
  • [2] Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2-metastatic breast cancer (MBC)
    Rugo, H. S.
    Schmid, P.
    Tolaney, S. M.
    Dalenc, F.
    Marme, F.
    Shi, L.
    Verret, W.
    Gharaibeh, M.
    Bardia, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1258 - S1258
  • [3] Health-related quality of life with sacituzumab govitecan in HR+/HER2-metastatic breast cancer in the phase III TROPiCS-02 trial
    Rugo, Hope S.
    Schmid, Peter
    Tolaney, Sara M.
    Dalenc, Florence
    Marme, Frederik
    Shi, Ling
    Verret, Wendy
    Shah, Anuj
    Gharaibeh, Mahdi
    Bardia, Aditya
    Cortes, Javier
    ONCOLOGIST, 2024, 29 (09): : 768 - 779
  • [4] Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)
    Rugo, H. S.
    Bardia, A.
    Marme, F.
    Cortes, J.
    Schmid, P.
    Loirat, D.
    Tredan, O.
    Ciruelos, E. M.
    Dalenc, F.
    Gomez Pardo, P.
    Jhaveri, K.
    Delaney, R. J.
    Valdez, T.
    Wang, H.
    Verret, W.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1386 - S1386
  • [5] Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2-metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial
    Marme, Frederik
    Bardia, Aditya
    Rugo, Hope
    Schmid, Peter
    Tolaney, Sara M.
    Oliveira, Mafalda
    Schneeweiss, Andreas
    Shi, Ling
    Verret, Wendy
    Gharaibeh, Mahdi
    Shah, Anju
    Cortes, Javier
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2-metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.
    Bardia, Aditya
    Rugo, Hope S.
    Cortes, Javier
    Tolaney, Sara M.
    Schmid, Peter
    Motwani, Monica
    Yoon, Oh Kyu
    Boice, Jillian
    Zhuo, Luting
    Marme, Frederik
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)
    Cortes, J.
    Marme, F.
    Schmid, P.
    Rugo, H. S.
    Tolaney, S. M.
    Verret, W.
    Valdez, T.
    Huo, Y.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S343 - S344
  • [8] Sacituzumab Govitecan (SG) vs Treatment of Physician's Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2-Metastatic Breast Cancer (mBC)
    Rugo, Hope
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Loirat, Delphine
    Tredan, Olivier
    Ciruelos, Eva
    Dalenc, Florence
    Pardo, Patricia Gomez
    Jhaveri, Komal
    Motwani, Monica
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Genomic alterations in DNA damage response (DDR) genes in HR+/HER2-metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study
    Bardia, Aditya
    Zhang, Yi
    Marme, Frederik
    Schmid, Peter
    Cortes, Javier
    Tolaney, Sara M.
    Zhang, Yajia
    Yoon, Oh Kyu
    Verret, Wendy
    Das Thakur, Meghna
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
12345